Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial

Jose I. Bernardino, Amanda Mocroft, Cedrick Wallet, Stéphane De Wit, Christine Katlama, Peter Reiss, Patrick W. Mallon, Laura Richert, Jean Michel Molina, Hernando Knobel, Philippe Morlat, Abdel Babiker, Anton Pozniac, Francois Raffi, Jose R. Arribas

    Research output: Contribution to journalArticleResearch

    9 Citations (Scopus)

    Abstract

    © 2019 Bernardino et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Background Comparison of changes in body composition, adipokines and inflammatory markers after initial therapy with a nucleos(t)ide reverse transcriptase inhibitor (N(t)RTI)- sparing or containing regimen are scarce. Design Randomised Clinical Trial. Methods This is the body composition substudy of NEAT 001/ANRS 143, a randomised trial comparing darunavir/ritonavir (DRV/r) plus either raltegravir (RAL) or tenofovir disoproxil fumarate/ emtricitabine (TDF/FTC) in 805 ART naïve HIV-infected adults. The primary endpoint was percentage change in limb fat at week 96. Secondary endpoints were associations among these changes and metabolic markers (IL-6, insulin, leptin, adiponectin, FGF-23). Results 126 subjects (61 DRV/r + RAL and 65 DRV/r + TDF/FTC) were included. The rate of change in BMI between groups for RAL versus TDF/FTC at week 96 was 1.5% per 48-week period (p = 0.015). The rate of change in limb fat mass, trunk fat mass, total body fat and total lean mass was for RAL versus TDF/FTC at week 96 was 2.5% (p = 0.38), 7.3% ((p = 0.021), 4.9% (p = 0.061) and 1.3% (p = 0.12) respectively. Baseline insulin and leptin levels were correlated with baseline limb fat and trunk fat mass [r = 0.31 (p = 0.0043)/r = 0.28 (p = 0.0011) for limb fat, and r = 0.63 (p<0.0001)/r = 0.50(p<0.0001) for trunk fat]. After adjustment, a 10% faster increase in leptin between baseline and week 48 was associated with a more rapid increase in limb fat at week 48 (0.5% per 48 weeks, p<0.001), total body fat mass (0.6% per 48 weeks, p<0.001), and trunk fat mass (0.3% per 48 weeks, p = 0.0026). Conclusions After week 96 a N(t)RTI sparing regimen of DRV/r + RAL produced a numerically greater percentage increase in body composition variables with only change in trunk fat mass and BMI being significant.
    Original languageEnglish
    Article number0209911
    Number of pages13
    JournalPLoS ONE
    Volume14
    Issue number1
    DOIs
    Publication statusPublished - 28 Jan 2019

    Keywords

    • Adipokines/blood
    • Adult
    • Body Composition
    • Body Mass Index
    • Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination/administration & dosage
    • Female
    • Humans
    • Male
    • Raltegravir Potassium/administration & dosage
    • Time Factors
    • RISK
    • PROTEASE INHIBITORS
    • NUCLEOSIDE
    • REVERSE-TRANSCRIPTASE INHIBITORS
    • THERAPY
    • HIV
    • IMMUNE ACTIVATION
    • LIPODYSTROPHY
    • ANTIRETROVIRAL-NAIVE ADULTS

    Fingerprint

    Dive into the research topics of 'Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial'. Together they form a unique fingerprint.

    Cite this